See more : Sirius Real Estate Limited (SRRLF) Income Statement Analysis – Financial Results
Complete financial analysis of VioQuest Pharmaceuticals, Inc. (VOQP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VioQuest Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- S&U plc (47IE.L) Income Statement Analysis – Financial Results
- Companhia Energética do Rio Grande do Norte – COSERN (CSRN6.SA) Income Statement Analysis – Financial Results
- Naigai Trans Line Ltd. (9384.T) Income Statement Analysis – Financial Results
- H&R Real Estate Investment Trust (HRUFF) Income Statement Analysis – Financial Results
- Optical Cable Corporation (OCC) Income Statement Analysis – Financial Results
VioQuest Pharmaceuticals, Inc. (VOQP)
Industry: Biotechnology
Sector: Healthcare
About VioQuest Pharmaceuticals, Inc.
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company's products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors. VioQuest Pharmaceuticals also provides chiral products, technology, and custom synthesis development services to pharmaceutical and fine chemical companies in various stages of a products' lifecycle. The company was founded in 2000 and is headquartered in Basking Ridge, New Jersey.
| Metric | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 3.80M | 1.49M | 669.04K | 33.13K | 440.23K | 428.04K | 633.58K | 573.05K | 486.76K | 634.51K | 691.47K |
| Cost of Revenue | 0.00 | 0.00 | 2.43M | 837.65K | 196.05K | 31.52K | 331.66K | 276.57K | 386.59K | 372.90K | 373.52K | 429.92K | 457.07K |
| Gross Profit | 0.00 | 0.00 | 1.38M | 647.50K | 472.99K | 1.61K | 108.58K | 151.47K | 247.00K | 200.16K | 113.24K | 204.59K | 234.40K |
| Gross Profit Ratio | 0.00% | 0.00% | 36.20% | 43.60% | 70.70% | 4.86% | 24.66% | 35.39% | 38.98% | 34.93% | 23.26% | 32.24% | 33.90% |
| Research & Development | 4.99M | 1.82M | 9.39M | 902.16K | 440.65K | 1.03K | 13.36K | 11.87K | 14.67K | 20.68K | 20.63K | 32.18K | 11.07K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 147.18K | 132.05K | 153.56K | 159.95K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.93K | 27.70K | 29.78K | 52.50K |
| SG&A | 3.79M | 3.46M | 4.83M | 3.63M | 1.98M | 156.34K | 288.23K | 247.05K | 184.04K | 177.11K | 159.75K | 183.34K | 212.45K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.78M | 5.28M | 14.49M | 4.71M | 2.50M | 157.37K | 301.59K | 318.72K | 201.60K | 197.79K | 180.38K | 215.52K | 223.52K |
| Cost & Expenses | 8.78M | 5.28M | 16.92M | 5.55M | 2.70M | 188.89K | 633.25K | 595.29K | 588.19K | 570.68K | 553.90K | 645.43K | 680.59K |
| Interest Income | 0.00 | 105.70K | 42.55K | 38.27K | 13.97K | 41.43K | 39.00 | 1.29K | 0.00 | 695.00 | 0.00 | 1.59K | 194.00 |
| Interest Expense | 1.13M | 0.00 | 0.00 | 0.00 | 2.81K | 210.00 | 5.86K | 5.18K | 0.00 | 1.30K | 0.00 | 8.77K | 10.20K |
| Depreciation & Amortization | 1.20M | 6.30K | 266.51K | 475.42K | 323.52K | -374.17K | 48.95K | 59.80K | 2.89K | 8.73K | 10.88K | 9.45K | 13.49K |
| EBITDA | -6.61M | -5.15M | -10.35M | -3.59M | -1.71M | -371.75K | -144.07K | -107.45K | 48.28K | 11.10K | -56.26K | -1.48K | 24.37K |
| EBITDA Ratio | 0.00% | 0.00% | -337.67% | -241.49% | -255.00% | -659.20% | -32.89% | -25.11% | 7.62% | 1.94% | -11.56% | -0.23% | 3.52% |
| Operating Income | 9.74M | 5.28M | 13.11M | 4.06M | 2.03M | 155.76K | 193.02K | 167.25K | 45.40K | 2.37K | 67.14K | 10.93K | 10.88K |
| Operating Income Ratio | 0.00% | 0.00% | 344.67% | 273.50% | 303.36% | 470.10% | 43.84% | 39.07% | 7.17% | 0.41% | 13.79% | 1.72% | 1.57% |
| Total Other Income/Expenses | -2.09M | 0.00 | -8.12M | -336.73K | -2.03M | -537.98K | -391.10K | -167.25K | 0.00 | -1.31K | -67.14K | -10.93K | 0.00 |
| Income Before Tax | -10.87M | 0.00 | -13.07M | 0.00 | 0.00 | 218.41K | -198.09K | 167.28K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | -343.55% | 0.00% | 0.00% | 659.20% | -45.00% | 39.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -240.68K | 2.99M | -236.42K | -38.27K | -11.16K | 270.30K | 5.07K | 3.86K | 1.65K | 605.00 | 2.79K | 7.18K | 10.01K |
| Net Income | -10.89M | -8.27M | -12.83M | -4.02M | -2.02M | -51.88K | -198.09K | -171.10K | 43.75K | 1.77K | -69.93K | -18.11K | 875.00 |
| Net Income Ratio | 0.00% | 0.00% | -337.34% | -270.92% | -301.69% | -156.59% | -45.00% | -39.97% | 6.91% | 0.31% | -14.37% | -2.85% | 0.13% |
| EPS | -2.33 | -2.08 | -5.82 | -2.35 | -1.62 | -0.20 | -10.64 | -9.75 | 2.49 | 0.10 | -3.99 | -1.04 | 0.05 |
| EPS Diluted | -2.33 | -2.08 | -5.82 | -2.35 | -1.62 | -0.20 | -10.64 | -9.75 | 2.00 | 0.09 | -3.99 | -1.04 | 0.05 |
| Weighted Avg Shares Out | 4.67M | 3.98M | 2.20M | 1.71M | 1.25M | 253.41K | 18.62K | 17.55K | 17.54K | 17.54K | 17.54K | 17.38K | 18.88K |
| Weighted Avg Shares Out (Dil) | 4.67M | 3.98M | 2.20M | 1.71M | 1.25M | 253.41K | 18.62K | 17.55K | 21.86K | 19.54K | 17.54K | 17.38K | 18.88K |
Source: https://incomestatements.info
Category: Stock Reports